Surgalign Names Paolo Amoruso Chief Legal Officer and Corporate Secretary
August 04 2022 - 8:30AM
Surgalign Holdings, Inc., (NASDAQ: SRGA) a global medical
technology company focused on elevating the standard of care by
driving the evolution of digital health, today announced the
appointment of Paolo Amoruso as its new General Counsel and
Corporate Secretary, effective August 1, 2022. He previously served
as Interim General Counsel of Surgalign, having joined the Company
in April 2022.
Commenting on today’s appointment, Terry Rich, President and
Chief Executive Officer of Surgalign stated, “Paolo has been an
invaluable member of our team since taking on the role of Interim
General Counsel just a few months ago. He has quickly immersed
himself on a variety of legal and business matters, has worked very
well with our leadership team and Board, and has the expertise we
need as we embark on the next phase of our corporate evolution. We
are excited to have him onboard as part of our team.”
Mr. Amoruso brings to Surgalign approximately 25
years of experience serving public companies in various legal,
financial and executive roles. He began his career with Shell Oil
Company as a Tax Attorney, served as Assistant General Counsel to
the International Division of Devon Energy Corporation, and later
served as Vice President of Legal and Commercial Affairs and
Corporate Secretary of Hyperdynamics Corporation. In 2016, he
joined McGowen & Fowler PLLC, a boutique energy law firm
specializing in corporate transactional matters, litigation and
mergers and acquisitions for small- to medium-sized public
companies. While with McGowen & Fowler, he was brought in by
the Board of Attis Oil and Gas (a UK-AIM listed company) to serve
as General Counsel and Executive Chairman of the Board, where he
led the restructuring and the subsequent reverse merger with Helium
One Global Ltd. Mr. Amoruso holds a Juris Doctorate, Master of
Business Administration, and Bachelor of Science in Economics from
the University of Houston and a Master in Tax Law from the NYU
School of Law.
“This is an exciting time to join Surgalign and
I am truly looking forward to the journey ahead,” stated Mr.
Amoruso. “The Company has so many opportunities for value creation
given its technology platform, relationships within the medical
community, and the markets it serves. I am honored to become part
of the team and will leverage my expertise to help unlock this
value for all stakeholders.”
About Surgalign Holdings, Inc.Surgalign
Holdings, Inc. is a global medical technology company committed to
the promise of digital health to drive transformation across the
surgical landscape. Uniquely aligned and resourced to advance the
standard of care, the company is building technologies physicians
and other health providers will look to for what is truly possible
for their patients. Surgalign is focused on developing solutions
that predictably deliver superior clinical and economic outcomes.
Surgalign markets products throughout the United States and in
approximately 50 countries worldwide through an expanding network
of top independent distributors. Surgalign is headquartered in
Deerfield, IL, with commercial, innovation and design centers in
San Diego, CA, Warsaw and Poznan, Poland, and Wurmlingen, Germany.
Learn more at www.surgalign.com and connect on LinkedIn and
Twitter.
Forward Looking StatementThis press release
contains forward-looking statements based on management’s current
expectations, estimates and projections about our products,
company, and industry, our management's beliefs, and certain
assumptions made by our management. Words such as "anticipates,"
"expects," "intends," "plans," "believes," "seeks," "estimates,"
and other variations of such words and similar expressions are
intended to identify such forward-looking statements. These
statements are not guarantees of future performance and are subject
to risks and uncertainties, including the risks described in our
public filings with the U.S. Securities and Exchange Commission
(SEC). Our actual results may differ materially from the
anticipated results reflected in these forward-looking statements.
Copies of the company's SEC filings may be obtained by contacting
the company or the SEC or by visiting Surgalign's website at
www.surgalign.com or the SEC’s website at www.sec.gov.
Investor and Media Contact: |
|
Surgalign Contact: |
Glenn Wiener |
|
Kristine Simmons |
gwiener@gwcco.com |
|
ksimmons@surgalign.com |
+1 917 887-8434 |
|
+1 619 206 4648 |
Surgalign (NASDAQ:SRGA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Surgalign (NASDAQ:SRGA)
Historical Stock Chart
From Apr 2023 to Apr 2024